Advertisement
A paper on Covaxin’s neutralization potential against the UK strain has been accepted for publication, he said here on Thursday while addressing an international webinar ”KeralaHealth: Making the SDG A Reality,” organized by the Department of Health and Family Welfare, Government of Kerala.
In the case of the variants from South Africa and Brazil, efforts were on to isolate the mutated virus strains from the samples collected from travelers from these two countries, he said.
The official said the third clinical trial of CovaxinBB152 had been completed as all the 25,800 volunteers involved in the exercise had been administered both doses.
Related Articles
Advertisement
Dr. Bhargava pointed out that India was the fifth country in the world to isolate the Covid-19 virus as part of the efforts to develop a vaccine for the pandemic.
With its graded response to the outbreak of Covid-19right from the beginning, India had successfully kept the spread of the pandemic under control while utilizing this period for drastically scaling up the capacity of the country’s medical infrastructure, both under the government and the private sector.
India had from the outset resisted the temptation of going for herd immunity unlike many European countries, including the UK and Italy, and its decision had been vindicated from what happened in the western nations that allowed the pandemic to spread, he pointed out.
As a result, India had not only ramped up its medical infrastructure for domestic use but had also reached the level of exporting vaccines and treatment kits on a large scale, he said.
The webinar series that began on February 17, with a focus on the prospects of achieving sustainable development goals (SDGs) amid an added challenge posed by Covid-19, is held across five days this month and early March.